DUBLIN-(BUSINESS WIRE)–The report “Respiratory Infection Diagnostics Markets by Technology, Plex, Place, Product and by Region with Guides for Executives and Consultants” has been added to ResearchAndMarkets.com supply.
COVID-19 has opened up the market for respiratory infection testing in healthcare settings. Now the race for market share begins in earnest.
Big new markets are opening up. In healthcare facilities, clinics, doctor’s offices and other places. And let’s not forget the market for screening not just for COVID, but for the other 20 respiratory pathogens as well. Multiplex vs single plex? Explore a rapidly changing market as competitors vie for positions in new markets that are not yet well understood.
The new technology is forever changing the diagnosis of respiratory infections. Reducing time to result opens up markets many times larger than current microbiology-based practice. The diagnosis has already been moved to the Emergency. It now moves to the doctor’s office lab. Could Home be next?
Multiplex factors are creating confusion in the marketplace while reducing costs and improving care, but important factors are impeding progress. The widespread nature of respiratory infections (young people can get 8 colds a year) means the potential size of the market is huge. Respiratory, already the largest category of infectious diseases, may multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and risk with this in-depth report.
Our research makes you an expert in your organization. Put our research team to work for you by ordering all or part of this comprehensive report. Help and additional specific data are provided at no additional charge.
Make investment decisions and valuations with confidence using the latest data with five-year market forecasts.
Market directories
-
Respiratory Infections Dx Market, Situation Analysis and Impact of COVID-19
-
A guide for managers, marketing, sales and business development staff
-
A Guide for Management Consultants and Investment Advisors
Market overview
Respiratory infections
-
Top vs. Bottom – Marketing Implications
-
Understanding the role of pneumonia
-
Bacterial infections
-
Tuberculosis is a special case
-
Viral infections
-
COVID-19
-
Fungal and other pathogens
Diagnosis – a changing role
-
Historical practice
-
Current diagnostics
-
The multiplex vector
-
Future diagnostics – the question of when and where
-
Diagnosis of respiratory infections – the destination
-
Diagnostics as a defensive weapon
COVID-19
-
Pandemic diagnostics
-
Risk Management – Spark and Spread
-
Dx technology – nucleic acid based
-
Dx technology – immunoassay and serology
-
Time to market and readiness issues
-
The unrecognized role of the multiplex in managing the pandemic
Market trends
Growth promoting factors
-
Syndromic multiplexing
-
TAT
-
Antimicrobial resistance movement
-
Mitigating the pandemic
-
An aging population at risk
Factors limiting growth
-
The cost curve
-
Regulation and coverage
-
Let it be
Instrumentation and automation
-
The Shrinking Multiplexer
-
Bioinformatics networks and anonymous reporting
Development of diagnostic technologies
-
The key role of time to result
-
Single cell genomics is changing the picture
-
Pharmacogenomics obscures diagnosis and treatment
-
Identifying pathogens – a planned timeline for the future
Diagnosis of respiratory infections Recent developments
-
Genomtec Receives CE-IVD Mark for POC Test for Respiratory Diseases
-
FDA issues first EUA for over-the-counter COVID-19/influenza/RSV test
-
Real World Diagnostics Plans Third Generation POC Platform
-
Cue Health is targeting the DTC market
-
Investors are skeptical of Quidel’s acquisition of Ortho Clinical Diagnostics
-
Sense Biodetection to debut instrument-free POC MDx
-
LGC develops ‘ultra-high-throughput’ anti-COVID workflow.
-
Review health filings for IPOs for up to $100 million
-
QuantuMDx Multiplex System Development, Syndrome Panels
-
Bio-Rad Laboratories receives CE mark for RT-PCR assay respiratory kit
-
BforCure Prepares multiple panels for PoC qPCR platform
-
Angstrom Bio raises $3 million in private funding
-
Test them all
-
Hologic banking on MDx acquisitions
-
Pandemic brings handheld qPCR devices closer to commercialization
-
Talis Biomedical’s 2020 revenue rises sharply
-
Luminex to develop test for Covid/Influenza/RSV
-
Becton Dickinson Charts Transition of COVID Diagnostics
-
MiRxes Receives Approval for Multiplex Covid/Influenza Test
-
A new silicon-based assay for infectious disease screening
-
GenMark to Meet Demand for Respiratory Panel
-
Tempus Announces COVID-19 Testing, Data Initiative
-
Abacus Diagnostica Reading Multiplex Respiratory Test
-
Qiagen acquires NeuMoDx Molecular
-
Companies move to multiplex testing for SARS-CoV-2, flu
-
Novacyt receives CE mark for coronavirus, influenza, RSV combination panel
-
Cepheid debuts 10-color technology with new TB test
-
BioMerieux Pneumonia Panel Can Improve Care
-
Mammoth Biosciences Announces CRISPR-Based C19 Diagnostics
-
Genetic Signatures receives CE mark for C19 molecular test
-
Qiagen respiratory panel with C19 receives CE mark
-
Lumos Diagnostics closes $15M Series A funding
-
Fusion Genomics to evaluate NGS analysis of the respiratory tract
-
C19 Test Development by Co-Diagnostics
-
Rapid Diagnostics completes acquisition of Enigma Diagnostics
-
A flu-like epidemic could kill 80 million worldwide
-
A startup developing AI to detect tuberculosis
-
Nipah virus is a global threat
Profiles of key players
-
Abacus Diagnostica
-
Abbott Laboratories
-
Speeding up diagnostics
-
Access to bio
-
Ador Diagnostics
-
ADT Biotech
-
Akonni Biosystems
-
Altona Diagnostics
-
Alveo Technologies
-
Anatolia Geneworks
-
Antelope Dx
-
BioCode attached
-
Assurance Scientific Laboratories
-
Golden diagnostics
-
Aus diagnostics
-
Beckman Coulter diagnosis
-
Becton, Dickinson and Company
-
Cheers to Binx
-
Biocartis
-
BioFire diagnostics (bioMerieux)
-
bioMerieux Diagnostics
-
Bio-Rad Laboratories, Inc.
-
Bosch Healthcare Solutions GmbH.
-
Celiac disease
-
Cepheid (Danacher)
-
Chembio
-
Co. Diagnostics
-
Credo Diagnostics Biomedical
-
Cue Health
-
Curetis NV/Curetis GmbH
-
Discovery
-
Diagenous diagnosis
-
Diascopic
-
Diasorin SpA
-
Enzo Biochem
-
Eurofins Scientific
-
Fluxergy
-
Fulgent Genetics
-
Fusion Genomics.
-
Genetic signatures
-
GenMark Dx (Roche)
-
Hibergene Diagnostics
-
Hologic
-
Immuneexpress
-
Inflammatics
-
Invetech
-
Janssen Diagnostics
-
a warrior
-
Lexicons
-
LightDeck Diagnostics
-
Luminex Corp
-
Lumos Diagnostics
-
Mammoth Biosciences
-
Maxim Biomedical
-
Meridian Bioscience
-
Mesa Biotech (Thermo Fisher)
-
Millipore Sigma
-
Mindray
-
Mobidiag (Hologic)
-
Mologic
-
Nanomix
-
Operon
-
Oxford Nanopore Technologies
-
Panagen
-
Perkin Elmer
-
Prenetics
-
Primerdesign (Novacite)
-
Prominex
-
Qiagen
-
QuantuMDx
-
Quidel
-
Roche Molecular Diagnostics
-
Sijin
-
Siemens Healthineers
-
Sona Nanotech
-
SpeedDx
-
T2 biosystems
-
Talis Biomedical
-
Thermo Fisher Scientific Inc.
-
Veramarx
-
Veredus Laboratories
-
Visby Medical
-
XCR diagnostics
-
Zhejiang Orient Gene Biotech
For more information on this report, visit https://www.researchandmarkets.com/r/qcjynn
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We bring you the latest data on international and regional markets, key industries, leading companies, new products and the latest trends.